Get access

Radiolabeled Heterobivalent Peptidic Ligands: an Approach with High Future Potential for in vivo Imaging and Therapy of Malignant Diseases

Authors

  • Gabriel Fischer,

    1. Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1–3, 68167 Mannheim (Germany)
    Search for more papers by this author
  • Prof. Dr. Ralf Schirrmacher,

    1. McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC (Canada)
    Search for more papers by this author
  • Prof. Dr. Björn Wängler,

    1. Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim (Germany)
    Search for more papers by this author
  • Dr. Carmen Wängler

    Corresponding author
    1. Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1–3, 68167 Mannheim (Germany)
    2. Department of Nuclear Medicine, University Hospital Munich, Ludwig Maximilians University Munich, Munich (Germany)
    • Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1–3, 68167 Mannheim (Germany)

    Search for more papers by this author

Abstract

original image

Two-pronged synergism: We review the recently developed approach of using heterobivalent peptide ligands that interact concomitantly with different receptors on tumor cells. These ligands exhibit highly favorable tumor-targeting properties and pave the way for the development of drugs for specific, sensitive, and noninvasive tumor imaging and therapy.

Ancillary